IGAS

Dettol Pro Solutions Shares How to Help Prevent Spread of Strep A Via Proper Cleaning Protocols and Product Selection

Retrieved on: 
Wednesday, January 18, 2023

GAS infections often present as a mild sore throat ('strep throat') and skin/soft tissue infections such as impetigo and cellulitis1.

Key Points: 
  • GAS infections often present as a mild sore throat ('strep throat') and skin/soft tissue infections such as impetigo and cellulitis1.
  • Dettol Pro Solutions, which consists of a team of in-house virologists, microbiologists and medical scientists, was launched in the UK last year.
  • Dettol Pro Solutions’ products are demonstrated to kill 99.9% of bacteria and enveloped viruses including Streptococcus A, Covid-19 and Influenza6.
  • For further information and advice from Dettol Pro Solutions, please visit https://www.reckittpro.co.uk .

iGAS USA OPENS TWO NEW PRODUCTION FACILITIES IN ABU DHABI

Retrieved on: 
Friday, December 9, 2022

ABU DHABI, UAE, Dec. 10, 2022 /PRNewswire/ -- iGas USA, one the world's largest refrigerant gas suppliers, announces the opening of their two, new state-of-the-art production facilities in Abu Dhabi as follows: Their 2 million sq. ft. newly-constructed refrigerant production facility located on 40-acres of land and their 80,000 sq. ft. cylinder production facility with fully-automated production lines set to manufacture DOT disposable refrigerant cylinders. The two factory openings demonstrate the versatility and unique nature of iGas USA, which produces both refrigerant gas and metal cylinders within one global company.

Key Points: 
  • ft. Cylinder Production Facility for DOT Disposable Refrigerant Cylinders**
    ABU DHABI, UAE, Dec. 10, 2022 /PRNewswire/ -- iGas USA, one the world's largest refrigerant gas suppliers, announces the opening of their two, new state-of-the-art production facilities in Abu Dhabi as follows: Their 2 million sq.
  • ft. cylinder production facility with fully-automated production lines set to manufacture DOT disposable refrigerant cylinders.
  • At the forefront, iGas promotes the production, efficiency, and quality of refrigerant gas that has set the market standard.
  • For more information, visit the IGas USA website to learn more about their wide range of products.

iGAS USA OPENS TWO NEW PRODUCTION FACILITIES IN ABU DHABI

Retrieved on: 
Friday, December 9, 2022

ABU DHABI, UAE, Dec. 9, 2022 /PRNewswire/ -- iGas USA, one the world's largest refrigerant gas suppliers, announces the opening of their two, new state-of-the-art production facilities in Abu Dhabi as follows: Their 2 million sq. ft. newly-constructed refrigerant production facility located on 40-acres of land and their 80,000 sq. ft. cylinder production facility with fully-automated production lines set to manufacture DOT disposable refrigerant cylinders. The two factory openings demonstrate the versatility and unique nature of iGas USA, which produces both refrigerant gas and metal cylinders within one global company.

Key Points: 
  • ft. Cylinder Production Facility for DOT Disposable Refrigerant Cylinders**
    ABU DHABI, UAE, Dec. 9, 2022 /PRNewswire/ -- iGas USA, one the world's largest refrigerant gas suppliers, announces the opening of their two, new state-of-the-art production facilities in Abu Dhabi as follows: Their 2 million sq.
  • ft. newly-constructed refrigerant production facility located on 40-acres of land and their 80,000 sq.
  • ft. cylinder production facility with fully-automated production lines set to manufacture DOT disposable refrigerant cylinders.
  • At the forefront, iGas promotes the production, efficiency, and quality of refrigerant gas that has set the market standard.

FDA Makes Low-Risk Determination for Marketing of Products from Genome-Edited Beef Cattle After Safety Review

Retrieved on: 
Monday, March 7, 2022

This is the FDA's first low-risk determination for enforcement discretion for an IGA in an animal for food use.

Key Points: 
  • This is the FDA's first low-risk determination for enforcement discretion for an IGA in an animal for food use.
  • "It also demonstrates our ability to identify low-risk IGAs that don't raise concerns about safety, when used for food production.
  • Although PRLR-SLICK cattle have an equivalent trait to those cattle with a naturally-occurring short hair coat, they are not currently in commerce.
  • Further, the food from the cattle is the same as food from conventionally bred cattle that have the same slick-hair trait.

DGAP-News: DEFENCE THERAPEUTICS VACCINES AND PROGRAM DEVELOPMENT

Retrieved on: 
Tuesday, November 30, 2021

Vancouver, BC, Canada, November 30th 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), is a publicly-traded biotechnology company working on engineering the next generation vaccines, Antibody Drug Conjugates, ADC products, and cancer therapeutics using its proprietary AccumTM platform.

Key Points: 
  • Vancouver, BC, Canada, November 30th 2021 - Defence Therapeutics Inc. ("Defence" or the "Company"), is a publicly-traded biotechnology company working on engineering the next generation vaccines, Antibody Drug Conjugates, ADC products, and cancer therapeutics using its proprietary AccumTM platform.
  • The core of Defence Therapeutics platform is its AccumTM technology, which enables precision delivery of proteins of pharmacological interest to target cells and increases the intracellular accumulation to these targeted cells.
  • Another infectious disease vaccine in development at Defence Therapeutics is AccuVAC-PT009 targeting HPV.
  • Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform.